Journal
JOURNAL OF BONE ONCOLOGY
Volume 10, Issue -, Pages 36-40Publisher
ELSEVIER
DOI: 10.1016/j.jbo.2017.11.005
Keywords
Osteosarcoma; Limb salvage; Chemotherapy; Surgery; Infection
Categories
Funding
- National Natural Science Foundation of China [81372322, 81460440]
- Joint Special Funds for the Department of Science and Technology of Yunnan Province-Kunming Medical University [2014FB059]
- Scientific Research Projects of Internal Research Institutions of Medical and Health Units in Yunnan Province [2017NS196, 2017NS197]
- Tumor Hospital of Yunnan Province [BSJJ201406]
Ask authors/readers for more resources
Osteosarcoma is the most common primary malignant bone tumor; its standard treatment includes neoadjuvant chemotherapy combined with surgery. Neoadjuvant chemotherapy has significantly improved the 5-year survival and limb salvage rates in osteosarcoma since the 1870s. The survival rate of patients with limb salvage was not inferior to that of amputees, and therefore, limb salvage has become the main surgical option for patients with osteosarcoma. The 5-year survival rate for osteosarcoma has plateaued. However, new advances in limb salvage therapy in osteosarcoma, including adjuvant chemotherapy, ablation techniques, bone transport techniques, and computer navigation techniques, are now available. This report summarizes the recent advances in limb salvage therapy for osteosarcoma over the past decade.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available